Wall Street Zen Downgrades Enliven Therapeutics (NASDAQ:ELVN) to Sell

Enliven Therapeutics (NASDAQ:ELVN) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Several other research analysts also recently commented on the stock. JonesTrading raised their price objective on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. HC Wainwright boosted their target price on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Guggenheim dropped their target price on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Thursday. The Goldman Sachs Group raised their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Stifel Nicolaus lifted their price target on Enliven Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $72.67.

Enliven Therapeutics Price Performance

NASDAQ ELVN opened at $60.46 on Friday. The company has a market cap of $4.43 billion, a PE ratio of -36.20 and a beta of 0.27. Enliven Therapeutics has a 52 week low of $14.78 and a 52 week high of $62.32. The firm’s 50-day simple moving average is $48.62 and its two-hundred day simple moving average is $39.77.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities research analysts anticipate that Enliven Therapeutics will post -1.67 EPS for the current year.

Insider Transactions at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction dated Friday, July 17th. The stock was sold at an average price of $52.64, for a total transaction of $316,787.52. Following the completion of the transaction, the chief financial officer directly owned 46,054 shares in the company, valued at $2,424,282.56. The trade was a 11.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the company’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the transaction, the director owned 87,373 shares in the company, valued at $5,260,728.33. This represents a 64.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 190,831 shares of company stock valued at $10,991,723. 3.00% of the stock is currently owned by company insiders.

Institutional Trading of Enliven Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of ELVN. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after buying an additional 594 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Enliven Therapeutics by 4.3% during the 2nd quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock worth $440,000 after acquiring an additional 913 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after acquiring an additional 930 shares during the last quarter. KBC Group NV purchased a new position in Enliven Therapeutics in the first quarter worth $38,000. Finally, Swiss National Bank grew its position in Enliven Therapeutics by 1.7% in the fourth quarter. Swiss National Bank now owns 64,273 shares of the company’s stock worth $990,000 after acquiring an additional 1,100 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.